Sadeer Hannush, MD
Ophthalmology · Langhorne, PANPI 1780637942
Payments from drug & device makers
Across 47 payments — averaging $694.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kowa Research Institute, Inc.$29K
- Kowa Pharmaceuticals America, Inc.$1K
- Biotissue Holdings Inc.$344
- Sight Sciences, Inc.$261
- Alcon$245
- Rxsight Inc$234
- plus $994 from 13 others
What the payments were for
- Consulting fees$29,10089%
- Speaking & faculty fees$1,4674%
- Travel & lodging$1951%
- Food & beverage$1,8846%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kowa Research Institute, Inc. | 5 | $29,100 |
| Kowa Pharmaceuticals America, Inc. | 1 | $1,467 |
| Biotissue Holdings Inc. | 3 | $344 |
| Sight Sciences, Inc. | 2 | $261 |
| Alcon | 4 | $245 |
| Rxsight Inc | 2 | $234 |
| Abbott | 10 | $216 |
| KOWA Company, LTD. | 2 | $211 |
| Carl Zeiss Meditec, Inc. | 1 | $106 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $79 |
| Eyepoint US, Inc. | 1 | $78 |
| Dompe US, Inc. | 2 | $71 |
| Genentech USA, Inc. | 3 | $70 |
| Thea Pharma Inc. | 3 | $60 |
| Carl Zeiss Meditec USA, Inc. | 1 | $43 |
| Tarsus Pharmaceuticals, Inc. | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Bausch & Lomb Americas Inc. | 1 | $14 |
| Rapid Pathogen Screening, Inc. | 3 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,645 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Loteprednol Etabonate | 219 | $37,646 |
| InveltysLoteprednol Etabonate | 28 | $15,719 |
| Lotemax SmLoteprednol Etabonate | 53 | $13,142 |
| Prednisolone Acetate | 270 | $12,953 |
| Fluorometholone | 130 | $12,444 |
| ProlensaBromfenac Sodium | 32 | $11,013 |
| FlarexFluorometholone Acetate | 81 | $10,281 |
| TobradexTobramycin/Dexamethasone | 18 | $6,323 |
| BesivanceBesifloxacin Hcl | 19 | $4,602 |
| MoxifloxacinMoxifloxacin Hcl | 217 | $3,404 |
| ValacyclovirValacyclovir Hcl | 31 | $1,895 |
| Timolol Maleate | 94 | $642 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 39 | $602 |
| ErythromycinErythromycin Base | 59 | $580 |
| Acyclovir | 14 | $446 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Langhorne
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.